DUBLIN–(BUSINESS WIRE)–The “Mumps
– Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s
Mumps – Pipeline Review, H1 2019 provides comprehensive
information on the therapeutics under development for Mumps (Infectious
Disease), complete with analysis by stage of development, drug target,
mechanism of action (MoA), route of administration (RoA) and molecule
The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest
news and press releases. The Mumps (Infectious Disease) pipeline guide
also reviews of key players involved in therapeutic development for
Mumps and features dormant and discontinued projects.
The guide covers therapeutics under Development by
Companies/Universities/Institutes, the molecules developed by Companies
in Phase III, Phase II, Phase I and IND/CTA Filed stages are 2, 1, 2 and
1 respectively. Similarly, the Universities portfolio in Phase II and
Preclinical stages comprises 1 and 1 molecules, respectively.
Mumps (Infectious Disease) pipeline guide helps in identifying and
tracking emerging players in the market and their portfolios, enhances
decision making capabilities and helps to create effective counter
strategies to gain competitive advantage.
The pipeline guide provides a snapshot of the global therapeutic
landscape of Mumps (Infectious Disease).
The pipeline guide reviews pipeline therapeutics for Mumps (Infectious
Disease) by companies and universities/research institutes based on
information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of
development ranging from pre-registration till discovery and
The pipeline guide features descriptive drug profiles for the pipeline
products which comprise, product description, descriptive licensing
and collaboration details, R&D brief, MoA & other developmental
The pipeline guide reviews key companies involved in Mumps (Infectious
Disease) therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Mumps (Infectious Disease) therapeutics
based on mechanism of action (MoA), drug target, route of
administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued
The pipeline guide reviews latest news related to pipeline
therapeutics for Mumps (Infectious Disease)
Reasons to Buy
Procure strategically important competitor information, analysis, and
insights to formulate effective R&D strategies.
Recognize emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage.
Find and recognize significant and varied types of therapeutics under
development for Mumps (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
Develop tactical initiatives by understanding the focus areas of
Plan mergers and acquisitions meritoriously by identifying key players
and it’s most promising pipeline therapeutics.
Formulate corrective measures for pipeline projects by understanding
Mumps (Infectious Disease) pipeline depth and focus of Indication
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
Adjust the therapeutic portfolio by recognizing discontinued projects
and understand from the know-how what drove them from pipeline.
- Cadila Healthcare Ltd.
- GlaxoSmithKline PLC
- Sinovac Biotech Ltd.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/134okh
Laura Wood, Senior Press Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900